OptimizeRx (OPRX) Cash & Current Investments (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Cash & Current Investments data on file, last reported at $20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 21.7% year-over-year to $20.2 million; the trailing twelve-month figure through Mar 2026 stood at $20.2 million (up 21.7% YoY), and the FY2025 full-year result was $23.4 million, up 74.63% from the prior year.
• Cash & Current Investments retreated to $20.2 million in Q1 2026, from $23.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $89.0 million in Q1 2022 to a low of $13.4 million in Q4 2024.
• A 5-year average of $41.1 million and a median of $20.2 million in 2026 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slumped 81.32% in 2023 and jumped 74.63% in 2025, its largest moves.
• Tracing OPRX's Cash & Current Investments over 5 years: stood at $74.1 million in 2022, then tumbled by 81.32% to $13.9 million in 2023, then decreased by 3.41% to $13.4 million in 2024, then jumped by 74.63% to $23.4 million in 2025, then dropped by 13.68% to $20.2 million in 2026.
• Business Quant data shows OPRX's Cash & Current Investments at $20.2 million in Q1 2026, $23.4 million in Q4 2025, and $19.5 million in Q3 2025.